Tempest Therapeutics developed HCC therapeutics, obtaining FDA and EMA designations and initiating pivotal trials in China.
2 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tempest Therapeutics developed HCC therapeutics, obtaining FDA and EMA designations and initiating pivotal trials in China.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
Coverage
Newest first; wire copies grouped- GlobeNewswireTempest Reports Second Quarter 2025 Financial Results and Provides Business Update Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carc
- Unknown outlet